Release

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12

SAN DIEGO, Sept. 6, 2011 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday September 12, 2011 at 2:25 p.m. Eastern time, in the Metropolitan East Salon at the Waldorf=Astoria Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at http://www.adventrx.com/. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates. The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere®, which recently went off-patent. The Company is evaluating its Exelbine program following the complete response letter it received from the FDA. More information can be found on the Company's web site at http://www.adventrx.com/.

SOURCE ADVENTRX Pharmaceuticals